Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (244)	3/5/1999 12:10:00 PM
From: LLCF	Read Replies (1) \| Respond to of 3158

Chiron got a long winded but new recommendation from Morgan Stanley today... quite comprehensive. Posting here because it included this little statement which I'm sure they act apon: "Chiron could-and has the opportunity to become an important consolidator within the biotech industry. With an underleveraged financial structure (1.2 billion cash, 400 mill debt), a market capitalization of $4 billion, and a newly minted crack management team, Chiron could regain in industry-leading role by playing the role of consolidator. Its internal product pipeline is interesting, but early-stage. The opportunity lies with more than 1200 public and private fledgling, cash-strapped biotechnology companies available now at historic low valuations." Do you know is Rick working for Morgan now? :) DAK